PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Antisense therapy – Market size and forecast 2018-2023
• RNAi therapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Cardiovascular diseases
• Cancer
• Metabolic disorders
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Alnylam Pharmaceuticals
• Bausch Health
• Biogen
• Sarepta Therapeutics
PART 16: APPENDIX
• Research methodology
• List of abbreviations
PART 17: EXPLORE TECHNAVIO
Exhibit 01: Global biologic therapeutics market
Exhibit 02: Segments of global biologic therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: List of pipeline molecules for antisense and RNAi therapeutics
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antisense therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antisense therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: RNAi therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: RNAi therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Pipeline molecules for cancer treatment
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Alnylam Pharmaceuticals – Vendor overview
Exhibit 47: Alnylam Pharmaceuticals – Business segments
Exhibit 48: Alnylam Pharmaceuticals – Organizational developments
Exhibit 49: Alnylam Pharmaceuticals – Geographic focus
Exhibit 50: Alnylam Pharmaceuticals – Key offerings
Exhibit 51: Bausch Health – Vendor overview
Exhibit 52: Bausch Health – Business segments
Exhibit 53: Bausch Health – Organizational developments
Exhibit 54: Bausch Health – Geographic focu
Exhibit 55: Bausch Health – Segment focus
Exhibit 56: Bausch Health – Key offerings
Exhibit 57: Biogen – Vendor overview
Exhibit 58: Biogen – Business segments
Exhibit 59: Biogen – Organizational developments
Exhibit 60: Biogen – Geographic focus
Exhibit 61: Biogen – Key offerings
Exhibit 62: Sarepta Therapeutics – Vendor overview
Exhibit 63: Sarepta Therapeutics – Business segments
Exhibit 64: Sarepta Therapeutics – Organizational developments
Exhibit 65: Sarepta Therapeutics – Geographic focus
Exhibit 66: Sarepta Therapeutics – Key offerings
Exhibit 67: Validation techniques employed for market sizing
Exhibit 68: List of abbreviations
【掲載企業】
Alnylam Pharmaceuticals、Bausch Health、Biogen、Sarepta Therapeutics